Re­gen­eron inks $1B+ deal for glob­al rights to Sanofi-part­nered PD-1 Lib­tayo

Sanofi CEO Paul Hud­son made clear ear­li­er this year that his mis­sion to re­shape the com­pa­ny would in­volve some pipeline prun­ing. For the right price that ap­par­ent­ly in­cludes Lib­tayo, mere months ahead of an ex­pect­ed FDA de­ci­sion on lung can­cer.

Re­gen­eron is putting down a whop­ping $900 mil­lion up­front for the full rights to Lib­tayo, their part­nered PD-1 treat­ment that earned Re­gen­eron $306 mil­lion last year, up 13% from the year be­fore.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER